Assessment of hepatic fibrosis, portal hemodynamic changes, and disease severity in patients with HCV-related liver cirrhosis after sustained virologic response to direct-acting antiviral drugs (DAAs)

Egyptian Liver Journal

Table 5 Doppler ultrasound studies of the portal vein and hepatic artery before and after treatment

Item	Baseline “n = 100”	3 months after the end of treatment “n = 100”	12 months after the end of treatment “n = 100”	P value
PV flow velocity (mean ± SD) “cm/s”	18.73 ± 1.64	20.17 ± 2.57 P1 = 0.527	20.38 ± 2.79 P2 < 0.02*	P = 0.376 P3 < 0.04*
PV diameter (mean ± SD)” cm”	1.46 ± 0.03	1.37 ± 0.02	1.19 ± 0.04	P = 0.267
TAMV (mean ± SD) “cm/s”	13.01 ± 5.08	7.55 ± 2.37 P1 < 0.000***	8.09 ± 1.43 P2 < 0.000***	P < 0.02* P3 = 0.248
Cross-section area (mean ± SD) “cm²”	1.15 ± 0.77	1.10 ± 0.61 P1 = 0.481	0.94 ± 0.34 P2 = 0.211	P < 0.01* P3 = 0.217
Hepatic arterial resistive index (mean ± SD)	0.632 ± 0.10	0.621 ± 0.08 P1 = 0.743	0.622 ± 0.08 P2 = 0.659	P = 0.341 P3 = 0.243
Congestion index (mean ± SD)	0.061 ± 0.27	0.054 ± 0.24	0.046 ± 0.1	P < 0.001**